Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women

An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway t...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 8; no. 5; pp. 2503 - 2513
Main Authors Grant, Delores J., Manichaikul, Ani, Alberg, Anthony J., Bandera, Elisa V., Barnholtz‐Sloan, Jill, Bondy, Melissa, Cote, Michele L., Funkhouser, Ellen, Moorman, Patricia G., Peres, Lauren C., Peters, Edward S., Schwartz, Ann G., Terry, Paul D., Wang, Xin‐Qun, Keku, Temitope O., Hoyo, Cathrine, Berchuck, Andrew, Sandler, Dale P., Taylor, Jack A., O’Brien, Katie M., Velez Edwards, Digna R., Edwards, Todd L., Beeghly‐Fadiel, Alicia, Wentzensen, Nicolas, Pearce, Celeste Leigh, Wu, Anna H., Whittemore, Alice S., McGuire, Valerie, Sieh, Weiva, Rothstein, Joseph H., Modugno, Francesmary, Ness, Roberta, Moysich, Kirsten, Rossing, Mary Anne, Doherty, Jennifer A., Sellers, Thomas A., Permuth‐Way, Jennifer B., Monteiro, Alvaro N., Levine, Douglas A., Setiawan, Veronica Wendy, Haiman, Christopher A., LeMarchand, Loic, Wilkens, Lynne R., Karlan, Beth Y., Menon, Usha, Ramus, Susan, Gayther, Simon, Gentry‐Maharaj, Aleksandra, Terry, Kathryn L., Cramer, Daniel W., Goode, Ellen L., Larson, Melissa C., Kaufmann, Scott H., Cannioto, Rikki, Odunsi, Kunle, Etter, John L., Huang, Ruea‐Yea, Bernardini, Marcus Q., Tone, Alicia A., May, Taymaa, Goodman, Marc T., Thompson, Pamela J., Carney, Michael E., Tworoger, Shelley S., Poole, Elizabeth M., Lambrechts, Diether, Vergote, Ignace, Vanderstichele, Adriaan, Van Nieuwenhuysen, Els, Anton‐Culver, Hoda, Ziogas, Argyrios, Brenton, James D., Bjorge, Line, Salvensen, Helga B., Kiemeney, Lambertus A., Massuger, Leon F. A. G., Pejovic, Tanja, Bruegl, Amanda, Moffitt, Melissa, Cook, Linda, Le, Nhu D., Brooks‐Wilson, Angela, Kelemen, Linda E., Pharoah, Paul D.P., Song, Honglin, Campbell, Ian, Eccles, Diana, DeFazio, Anna, Kennedy, Catherine J., Schildkraut, Joellen M.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.05.2019
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom‐designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high‐grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC. We sought to examine associations in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.
Bibliography:Funding information
This work was supported by the National Institues of Health (Genetic Associations and Mechanisms in Oncology (GAME‐ON) (U19‐CA148112); R01‐CA114343 and R01‐CA114343‐S1 for the genotyping, bioinformatics, and biostatistical analysis for MAY, NCO, TBO, and TOR; P30‐CA15083 for the Mayo Clinic Genotyping Shared Resource; R01‐CA142081 for AACES; R01‐CA112523 and R01‐CA87538 for DOV; R01‐CA58598, N01‐CN‐55424 and N01‐PC‐67001 for HAW; K07‐CA080668, R01‐CA95023, P50‐CA159981 and MO1‐RR000056 for HOP; R01‐CA122443, P30‐CA15083, and P50‐CA136393 for MAY; CA54281, CA164973, and CA63464 for MEC; R01‐CA76016 for NCO; R01‐CA54419 and P50‐CA105009 for NEC; UM1‐CA186107, P01‐CA87969, R01‐CA49449, UM1‐CA176726, and R01‐CA67262 for NHS; R01CA160669‐01A1 for OVA; P50‐CA159981 and R01‐CA126841 for RPC; Z01‐ES044005 and Z01‐ES049033 for SIS and the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences for SIS; U01‐CA71966 and U01‐CA69417 for STA; R01‐CA058860 for UCI; P01‐CA17054, P30‐CA14089, R01‐CA61132, N01‐PC67010, R03‐CA113148, R03‐CA115195, and N01‐CN025403 for USC; the Intramural Research Program of the National Cancer Institute for PLC); Nationaal Kankerplan (BEL), a Vanderbilt CTSA grant from the National Institutes of Health/National Center for Advancing Translational Sciences (ULTR000445 for BVU); the National Institutes of Health Research Cambridge Biomedical Research Centre and Cancer Research UK (for RMH; C490/A10119 and C490/A10124 for SEA; and Cambridge Cancer Centre for CAM); the Ovarian Cancer Research Fund (DKE); the Department of Defense (DAMD17‐02‐1‐0669 for HOP; DAMD17‐02‐1‐0666 for NCO; W81XWH‐10‐1‐02802 for NEC); the American Cancer Society Early Detection Professorship (SIOP‐06‐258‐01‐COUN) and the National Center for Advancing Translational Sciences (UL1TR000124) for LAX; the Mayo Foundation, the Minnesota Ovarian Cancer Alliance and the Katherine B. Andersen Foundation (for MAY); the Moffitt Cancer Center (P30‐CA076292), Merck Pharmaceuticals, the state of Florida, Hillsborough County and the city of Tampa (for MOF); Helse Vest, the Norwegian Cancer Society, and the Research Council of Norway (for NOR); Radboud University Medical Centre (for NTH); the OHSU Foundation (for ORE); the Canadian Institiues of Health (MOP‐86727 for OVA); Royal Marsden Hospital (for RMH); the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge (SEA); the Lon V Smith Foundation (LVS‐39420 for UCI); Princess Margaret Cancer Centre Foundation‐Bridge for the Cure (for UHN); The Eve Appeal (The Oak Foundation) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (for UKO); the California Cancer Research Program (00‐01389 V‐20170, 2II0200 for USC); the National Health and Medical Research Council of Australia (310670 and 628903 for WMH); Cancer Institute NSW (12/RIG/1‐17 and 15/RIG/1‐16 for WMH); Research Centers in Minority Institutes (RCMI), National Institute of Minority Health and Health Disparities; North Carolina Central University/University of North Carolina at Chapel Hill, U54 Cooperative Agreement Grant, National Cancer Institute (1U54MD012393‐02 DJG; 1U54CA156735‐01 for DJG, TOK, CH, JMS)
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.1996